Treats partial seizures. ANDA 214816, held by Msn. Tiagabine Hydrochloride.
As of Nov 16, 2026, ANDA 214816 (Tiagabine Hydrochloride), held by Msn, was first approved by FDA on Nov 16, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tiagabine hydrochloride tablet is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 16, 2021 | Original application | Approved | None posted |
| Tiagabine Hydrochloride2MG · tablet;oral | Tiagabine Hydrochloride | Rx |
| Tiagabine Hydrochloride4MG · tablet;oral | Tiagabine Hydrochloride | Rx |
| Tiagabine Hydrochloride12MG · tablet;oral | Tiagabine Hydrochloride | Rx |
| Tiagabine Hydrochloride16MG · tablet;oral | Tiagabine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters